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The central sleep apnea syndromes (CSAS) are characterized
by sleep disordered breathing associated with diminished or
absent respiratory effort, coupled with the presence of symp-
toms including excessive daytime sleepiness, frequent noctur-
nal awakenings, or both.
Background
The international classiﬁcation of sleep disorders (ICSD)-2 [1]
identiﬁes 6 different forms of CSAS: (1) primary central sleep
apnea, (2) central sleep apnea due to cheyne stokes breathing
pattern (CSBP), (3) central sleep apnea due to medical condi-
tion not cheyne stokes, (4) central sleep apnea due to high-alti-
tude periodic breathing, (5) central sleep apnea due to drug or
substance, and (6) primary sleep apnea of infancy.
The underlying pathophysiology of central sleep apnea is
due to one of two mechanisms; hyperventilation or hypoventi-
lation. Central sleep apnea due to hypoventilation results from
the removal of the wakefulness stimulus to breathe in patients
with compromised neuromuscular ventilatory control. This is
typically noted in patients with central nervous system disease
(e.g., encephalitis), neuromuscular disease, or severe abnor-
malities in pulmonary mechanics (e.g., kyphoscoliosis [2]).
CSBP or cheyne-stokes respiration (CSR) is characterized
by an absence of air ﬂow and respiratory effort followed by
hyperventilation in a crescendo-decrescendo pattern. CSR
most often occurs in patients with congestive heart failure
(CHF). The prevalence is estimated to be approximately
30% [3] to 40% [4] in patients with CHF. However, this respi-Peer review under responsibility of The Egyptian Society of Chest
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failure.
CSAS associated with high altitude can be seen during the
acclimatization period, during or after rapid ascent to high
altitudes, typically 4000 m or greater. Hyperventilation sec-
ondary to altitude-associated hypoxia is thought to be the trig-
ger for high-altitude periodic breathing. Hence, individuals
with a heightened or brisk response to hypoxia are more likely
to develop CSAS due to high-altitude periodic breathing.[1]
Central sleep apnea due to drug or substance is primarily a
disorder related to opioid use. Patients who are on long-acting
opioids for at least 2 months appear to be at increased risk for
developing CSAS. The exact mechanism of opioid-related
CSAS is not well elucidated.Treatment of central sleep apnea syndromes (CSAS)
Primary CSAS
 Positive airway pressure (PAP) therapy may be considered
for the treatment of primary CSAS. PAP therapy offers
the following beneﬁts: (1) it has the potential to ameliorate
central respiratory events; (2) it typically does not confer
signiﬁcant risks; and (3) it is readily available in most cen-
ters. Therefore, PAP therapy can be considered for the
treatment of primary CSAS.
 Acetazolamide has limited supporting evidence but may be
considered for the treatment of primary CSAS yet, the use
of this drug should be weighed against the potential for side
effects including paresthesias, tinnitus, gastrointestinal
symptoms, metabolic acidosis, electrolyte imbalance, and
drowsiness.
 The use of zolpidem and triazolam may be considered for
the treatment of primary CSAS only if the patient does
not have underlying risk factors for respiratory depression.
Thus, due to the limited available evidence and the signiﬁ-
cant potential for adverse side effects especially respiratory
depression, the use of zolpidem and triazolam in the setting
of primary CSAS is not a preferable option and remains theis. Production and hosting by Elsevier B.V.
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2 Editoriallast therapeutic option, to be considered only if the other
therapeutic options listed above fail. Very close clinical fol-
low-up must be provided to consider the use of these hyp-
notic agents.CSAS due to CHF including CSBP and Not CSBP
 CPAP therapy targeted to normalize the apnea hypopnea
index (AHI) is indicated for the initial treatment of CSAS
related to CHF. The overall quality of evidence for the
use of CPAP in the setting of CSAS related to CHF is mod-
erate, but with a large effect size and consistent ﬁndings for
reduction of AHI and improvement in left ventricular ejec-
tion fraction (LVEF). CPAP treatment targeted to an
AHI < 15 has a positive effect on transplant-free survival
in patients with CSAS and CHF. An alternate treatment
option should be considered in the absence of adequate con-
trol of CSAS related to CHF with CPAP.
 BPAP therapy in a spontaneous timed (ST) mode targeted
to normalize the AHI may be considered for the treatment
of CSAS related to CHF only if there is no response to ade-
quate trials of CPAP, ASV, and oxygen therapies. Yet, no
recommendation can be made for this mode of BPAP until
further evidence is available.
 Adaptive Servo-Ventilation (ASV) targeted to normalize
the AHI is indicated for the treatment of CSAS related to
CHF.
 Nocturnal oxygen therapy is indicated for the treatment of
CSAS related to CHF. It should be noted that while oxygen
therapy does not confer outcome advantages over CPAP
therapy in the available evidence, supplemental oxygen
can be easily administered and can be given for those indi-
viduals with CSAS related to CHF who are unable to com-
ply with CPAP therapy. Consideration should be given to a
repeat sleep study with oxygen to ensure adequate resolu-
tion of central sleep apnea events.
 The following therapies have limited supporting evidence
but may be considered for the treatment of CSAS related
to CHF, after optimization of standard medical therapy,if PAP therapy is not tolerated, and if accompanied by close
clinical follow-up: acetazolamide and theophylline. These
pharmacological therapies require close monitoring.
CSAS due to medical condition not cheyne stokes: end-stage
renal disease (ESRD)
CPAP, supplemental oxygen, bicarbonate buffer use during
dialysis, and nocturnal dialysis are considered as possible treat-
ment options for CSAS related to ESRD.
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